The Department for Health and Social Care (DHSC) has published a new strategy ‘Data Saves Lives: Reshaping Health and Social Care with Data’. It seeks to drive innovation and improve efficiency across the NHS, while resetting the relationship with the public on health data. Senior Policy and Public Affairs Manager, Dr Emma Lawrence, outlines what this means for the life science sector, including our growing TechBio community.
Congratulations to Omass Therapeutics for raising $100 million in the Series B financing round, as well as two BIA member companies - Scotland-based EnteroBiotix and Solvemed group, who were featured in Forbes ‘30 under 30 Europe’ Science and Healthcare Edition for 2022. We are also glad to see engineering biology receive £20.6 million in investment from UK Research and Innovation (UKRI). Read more on IP TRIPS Waiver, update on Northern Ireland and BBSRC Business and Academia Prosperity Partnership.
It is great to see our ecosystem back out and about in person this Spring – and especially to be joined by 200 colleagues from across the biotech and life sciences sector at our London Regional event last week. The discussion on funding alternatives to IPO for scaling biotechs was both insightful and inspiring and provoked lots more conversations in the vibrant networking that followed. Read on for updates on WuXi healthcare forum, just published BIA quarterly influence report, Valneva approval and more...
Tim Powell, Partner at Powell Gilbert LLP and member of the BIA’s Intellectual Property Advisory Committee (IPAC), provides an update on latest progress towards a unitary patent (UP) and Unified Patent Court (UPC) in Europe and what this means for BIA members.
The Chancellor made his Spring Statement yesterday announcing a raft of changes across the tax system to address the current economic conditions for people and businesses in the UK. He laid out his vision to grow the economy with a focus on capital, people and ideas, and also provided a useful update on many important areas of tax policy for the life sciences and biotech sector.
Many of you will be aware that there have been reports this week from the World Trade Organisation in Geneva that the EU, South Africa, India and the US are agreeing a compromise on the waiver of intellectual property rights on COVID-19 vaccines. The key part of the compromise would be that developing countries that have exported less than 10% of the world’s vaccines in 2021, (so India but not China) would be able to authorise the use of a patented coronavirus vaccine without the patent owner’s consent.
Herbie Lambden recently joined the BIA team as Policy and Public Affairs Executive. In this blog, he shares his experience and key takeaways from the BIA Committee Summit which took place on 24th February.
Welcome to the first CEO blog of 2022, one I’m delighted not to have penned from an overpriced hotel room in San Francisco – my normal place of work this time of year. A new year normally means a fresh start, but it seems the year will again be dominated by how governments and global economies will respond to the COVID-19 pandemic.